13 completed, 5 active not recruiting, 5 recruiting, 2 terminated. 28 Phase 1, 15 Phase 2.
Follow Epileptic Syndromes: new trials by email Literature Review of Epileptic Syndromes trials Research Report on Epileptic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-11-02 |
| Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation nL-ATN1-001 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2025-11-06 | 2026-04-07 |
| Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies Ketogenic diet - Developmental and Epileptic Encephalopathies, Epileptic Spasms | Phase 1 | Terminated | Heather Olson | 1 | 2025-08-11 | 2026-10-14 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome CBD: GT4 Transdermal Delivery System - Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS) | Phase 1 / Phase 2 | Not yet recruiting | Alexander Rotenberg | 25 | 2025-01-01 | 2024-12-18 |
| A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease ION283 - Lafora Disease | Phase 1 / Phase 2 | Recruiting | Berge Minassian | 10 | 2024-12-03 | 2025-12-18 |
| A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE) NRTX-1001 - Epilepsy, Temporal Lobe | Phase 1 / Phase 2 | Recruiting | Neurona Therapeutics | 10 | 2024-11-14 | 2026-01-07 |
| Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-10-24 | 2026-07-13 |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy AAV9-hSyn1-miGRIK2 - Mesial Temporal Lobe Epilepsy | Phase 1 / Phase 2 | Recruiting | UniQure Biopharma B.V. | 12 | 2024-06-12 | 2026-08-24 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 5 | 2024-05-09 | 2026-06-08 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 4 | 2024-02-28 | 2025-11-14 |
| Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation nL-ATN1-002 - Dentatorubral-Pallidoluysian Atrophy | Phase 1 / Phase 2 | Active not recruiting | n-Lorem Foundation | 1 | 2024-02-21 | 2026-04-09 |
| Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD). Promoting Resilience in Stress Management (PRISM), Clinical-focused narrative (CFN) - Mitochondrial Diseases, Mitochondrial Myopathies | Phase 1 / Phase 2 | Completed | Children's Hospital of Philadelphia | 16 | 2023-09-22 | 2024-11-29 |
| Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK AUT00201, Placebo - Myoclonus Epilepsies, Progressive | Phase 1 | Completed | Autifony Therapeutics Limited | 6 | 2023-05-12 | 2025-03-25 |
| Exercise for Brain Regeneration in Epilepsy High-Impact Aerobic Exercise, Low-Impact Aerobic Exercise - Temporal Lobe Epilepsy | Phase 1 | Unknown | University of Southern California | 10 | 2022-08-20 | 2023-12-06 |
| Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies LP352, Placebo - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 1 / Phase 2 | Completed | Longboard Pharmaceuticals | 52 | 2022-03-03 | 2024-11-08 |
| Tricaprilin Infantile Spasms Pilot Study Tricaprilin - Infantile Spasm | Phase 1 | Completed | Cerecin | 8 | 2021-11-01 | 2024-09-19 |
| Bioavailability and Food Effect Study of 3 Types of Carisbamate Carisbamate - Healthy Subjects | Phase 1 | Completed | SK Life Science, Inc. | 33 | 2020-08-27 | 2021-10-07 |
| An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome STK-001 - Single Ascending Doses, STK-001 - Multiple Ascending Doses - Dravet Syndrome | Phase 1 / Phase 2 | Completed | Stoke Therapeutics, Inc | 62 | 2020-06-29 | 2025-05-18 |
Showing 20 of 28. Sign in to see all of them.
Epilepsies, Myoclonic (13) · Lennox Gastaut Syndrome (8) · Epilepsy (5) · Myoclonic Epilepsies, Progressive (4) · Spasms, Infantile (3) · Drug Resistant Epilepsy (2) · Epilepsy, Temporal Lobe (2) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (2) · Seizures (2) · CDKL5 deficiency disorder (1) · Epilepsy, Rolandic (1) · Hippocampal Sclerosis (1) · Lafora Disease (1) · Landau-Kleffner Syndrome (1)
Brain Diseases (28) · Central Nervous System Diseases (28) · Nervous System Diseases (28) · Epilepsy (23) · Epilepsy, Generalized (21) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11) · Genetic Diseases, Inborn (10) · Epilepsies, Myoclonic (6) · Epilepsies, Partial (3) · Congenital Abnormalities (2) · Heredodegenerative Disorders, Nervous System (2) · Malformations of Cortical Development (2) · Malformations of Cortical Development, Group I (2) · Myoclonic Epilepsies, Progressive (2)
Cannabidiol (3) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (3) · Diet, Ketogenic (1) · Levetiracetam (1) · Medical Marijuana (1) · Suspensions (1) · stiripentol (1) · tricaprylin (1)
Encoded Therapeutics (3) · SK Life Science, Inc. (3) · n-Lorem Foundation (3) · Alexander Rotenberg (1) · Autifony Therapeutics Limited (1) · Berge Minassian (1) · Biocodex (1) · Cerecin (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Hospital of Philadelphia (1) · Epygenix (1) · Gillette Children's Specialty Healthcare (1) · Heather Olson (1) · Ionis Pharmaceuticals, Inc. (1) · Longboard Pharmaceuticals (1)
United States (23) · Australia (4) · Canada (2) · United Kingdom (2) · France (1) · Singapore (1)
Marc Kamin, MD (2) · Salvador Rico, M.D., Ph.D (2) · Alexander Rotenberg, MD, PhD (1) · Ann Dandurand, MD (1) · Berge Minassian, MD (1) · Beverly S Wical, MD (1) · Colin VanOrman, MD (1) · Dennis J Dlugos, MD (1) · Eduardo Dunayevich, MD (1) · Elizabeth M McCormick, MS (1) · Francis Filloux, MD (1) · Hahn-Jun Lee, Ph.D. (1) · Jane Alcorn, PhD (1) · Jennifer Vannest, PhD (1)
PMID 27012680, PMID 27350662, PMID 31333569, PMID 41780062
R01NS065840 (1), U54NS078059 (1)